Suppr超能文献

支气管冲洗液上清液可作为晚期非小细胞肺癌基因组分析的新型液体活检标本。

Bronchial washing fluid supernatant serves as a novel liquid biopsy specimen for genome profiling in advanced non-small cell lung cancer.

作者信息

Wu Yongqing, Xie Yingbo, Chen Yu, Li Junjun, Li Bing, Liu Ming, Lin Xinqing, Xie Xiaohong, Zhou Chengzhi, Xie Zhanhong

机构信息

State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

Burning Rock Biotech, Guangzhou, China.

出版信息

Lung Cancer. 2025 Jul;205:108622. doi: 10.1016/j.lungcan.2025.108622. Epub 2025 Jun 9.

Abstract

BACKGROUND

Tumor tissue is the primary substrate for molecular testing in advanced lung cancer. However, obtaining sufficient tissue samples from biopsy for molecular testing often be challenging for some patients. Bronchial washing fluid supernatant (BWFS), which contains tumor-derived DNA, may serve as a supplement for genotyping. The aim of this study is to assess the efficacy and precision of detecting gene alterations in BWFS samples and evaluate their clinical potential.

PATIENTS AND METHODS

Thirty-eight stage III-IV non-small cell lung cancer (NSCLC) patients were prospectively enrolled between June 2022 and May 2024. The BWFS, matched tumor tissue (TIS), and plasma (PLA) from each patient were collected simultaneously, and all samples were subjected to targeted next-generation sequencing (NGS) of 520 cancer-related genes or 168 cancer-related genes.

RESULTS

In the cohort of 38 patients, 28 had simultaneous NGS results from three distinct samples. compared with PLA, BWFS contains more abundant tumor-derived DNA and exhibited a higher maximum allelic frequency (max_AF) and elevated mutation detection rate (BWFS: 96.4 %, PLA: 85.7 %), in concordance with TIS (BWFS: 96.4 %, TIS: 100 %). A total of 536 mutation events were detected from the three sample types (TIS: 225, BWFS: 209, PLA: 102). Using TIS as the gold standard, BWFS demonstrated superior sensitivity compared to PLA (78.22 % vs. 36 %). For different variations, copy number variations (CNVs) and fusions were more challenging to detect in PLA compared to BWFS. The estimates of tumor mutational burden (TMB) based on TIS and BWFS were highly correlated (Pearson r = 0.97).

CONCLUSION

Our study is the first to demonstrate that BWFS performs comparably to matched TIS and superiorly to PLA for genotyping advanced NSCLC via NGS. BWFS emerges as a valuable specimen, particularly in patients with insufficient tumor tissue.

摘要

背景

肿瘤组织是晚期肺癌分子检测的主要样本。然而,对一些患者来说,从活检中获取足够的组织样本用于分子检测往往具有挑战性。含有肿瘤来源DNA的支气管冲洗液上清液(BWFS)可作为基因分型的补充样本。本研究旨在评估BWFS样本中基因改变检测的有效性和准确性,并评估其临床应用潜力。

患者和方法

前瞻性纳入了2022年6月至2024年5月期间的38例III-IV期非小细胞肺癌(NSCLC)患者。同时收集每位患者的BWFS、匹配的肿瘤组织(TIS)和血浆(PLA),所有样本均进行520个癌症相关基因或168个癌症相关基因的靶向二代测序(NGS)。

结果

在38例患者队列中,28例患者同时获得了三种不同样本的NGS结果。与PLA相比,BWFS含有更丰富的肿瘤来源DNA,表现出更高的最大等位基因频率(max_AF)和更高的突变检测率(BWFS:96.4%,PLA:85.7%),与TIS一致(BWFS:96.4%,TIS:100%)。从三种样本类型(TIS:225个、BWFS:209个、PLA:102个)中共检测到536个突变事件。以TIS作为金标准,BWFS的灵敏度高于PLA(78.22%对36%)。对于不同类型的变异,与BWFS相比,PLA中检测拷贝数变异(CNV)和融合更具挑战性。基于TIS和BWFS的肿瘤突变负荷(TMB)估计值高度相关(Pearson相关系数r = 0.97)。

结论

我们的研究首次表明,通过NGS对晚期NSCLC进行基因分型时,BWFS的表现与匹配的TIS相当,且优于PLA。BWFS是一种有价值的样本,尤其对于肿瘤组织不足的患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验